Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur(Peter MacCallum Cancer Centre), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Caroline Robert(Institut Gustave Roussy), James Larkin(Royal Marsden Hospital), John B.A.G. Haanen(The Netherlands Cancer Institute), Reinhard Dummer(University of Zurich), Antoni Ribas(University of California, Los Angeles), David Hogg(Princess Margaret Cancer Centre), Omid Hamid(Angeles Clinic and Research Institute), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claus Garbe(University of Tübingen), Alessandro Testori(European Institute of Oncology), Michele Maio(University of Siena), Paul Lorigan(University of Manchester), Célèste Lebbé(Hôpital Saint-Louis), Thomas Jouary(Hôpital Saint-André), Dirk Schadendorf(Essen University Hospital), S. O'Day(Beverly Hills Cancer Center), John M. Kirkwood(University of Pittsburgh), Alexander M.M. Eggermont(Institut Gustave Roussy), Brigitte Dréno(Nantes Université), Jeffrey A. Sosman(Vanderbilt University), Keith T. Flaherty(Massachusetts General Hospital), Ming Yin(Genentech), Ivor Caro(Genentech), Suzanne Cheng(Roche (Switzerland)), Kerstin Trunzer(Roche (Switzerland)), Axel Hauschild(Kiel University)
Cited by 977
Abstract
Related Papers
No related papers found
Powered by citation graph analysis